The Sackler Family's Museum Donations: Reputation Laundering as a Documented Strategy

In March 2018 a small crowd gathered in the Temple of Dendur at the Metropolitan Museum of Art in New York, in the vast glass-walled hall officially called the Sackler Wing. At a signal they began throwing pill bottles into the reflecting pool around the ancient Egyptian temple, and lay down on the marble floor as if dead, scattering prescription slips. At the centre was the photographer Nan Goldin, who had nearly died of an OxyContin addiction and had founded a group called PAIN — Prescription Addiction Intervention Now — with a single demand: that museums take the Sackler name down. The image of bodies laid out beneath a name synonymous with high culture was arresting precisely because of the collision. This is the story of that name, of how it came to be carved above so many doors, and of the harder question underneath the protests: whether the philanthropy was a deliberate laundering strategy, ordinary rich-person vanity, or something that resists so clean a label.

The name that was everywhere

For the better part of half a century, the Sackler name was one of the most visible in the museum world, and almost nobody outside medicine connected it to a pill. It sat on the Sackler Wing at the Met, home to the Temple of Dendur. It sat on the Sackler Gallery of the Smithsonian in Washington, on galleries at the Louvre, on the Sackler Wing of the Royal Academy in London, on the Serpentine Sackler Gallery in Kensington Gardens, on rooms and institutes at Harvard, Yale, Oxford, Cambridge, Columbia and Tufts, on a wing of the Guggenheim, on space at the Tate, on a courtyard at the Victoria and Albert. In science the family endowed a stream of research: the Sackler name is attached to laboratories, professorships and even an astronomical body. Few philanthropic names of the twentieth century were spread so widely across the institutions that confer cultural legitimacy.

The scale of that spread is part of what made the eventual reckoning so disorienting. Visitors had walked through Sackler galleries for decades — schoolchildren on trips, tourists photographing the Temple of Dendur, students revising in Sackler libraries — without the faintest idea that the name belonged to anyone living, let alone to the owners of a pharmaceutical company. That invisibility was itself the point of the arrangement. A name carved in stone reads as history, as settled and honourable as the marble around it, and the honour transfers quietly to whoever holds it. For a family whose commercial identity was, by the 2000s, becoming a liability, having your surname read as a synonym for civilisation rather than for a controlled substance was worth more than any advertisement money could buy.

Much of that giving predates OxyContin by decades, and much of it flowed from Arthur Sackler, the eldest of the three brothers, who died in 1987 — nine years before the drug launched. Arthur was a genuine and voracious collector, especially of Asian art, and his gifts built real scholarship. His heirs have argued, with documentary support, that his fortune and his philanthropy had nothing to do with the opioid that later poisoned the family name, and that the sins of Purdue belong to the other branches. That distinction is inconvenient for a chant demanding “the Sackler name” come down, and it is also true, which is why an honest account has to hold both.

Where the giving became strategic

Here is the kernel that the litigation and journalism established, and it is more specific than the general suspicion that rich people give to museums to look good.

The general suspicion is, in the abstract, unremarkable — every wing named for a donor is in some sense a purchase of esteem. What the documents unsealed in the opioid litigation added was evidence that, at least for the Purdue-owning branches during and after the crisis, reputation management had become an explicit, discussed objective — the family and its advisers actively working to protect the name rather than simply enjoying the esteem their gifts happened to bring. Internal communications showed the family and its advisers acutely conscious of the family name, its association with the drug, and the need to protect it. As the litigation intensified in the late 2010s, the concern in the private record was visibly less about the giving as an end in itself and more about the name as an asset to be defended.

The most striking documented detail has nothing to do with the museums; it concerns the same instinct applied elsewhere: the internal exploration, discussed under the name Project Tango, of Purdue entering the addiction-treatment market — a plan to profit from the remedy to the dependence the company had helped create. It is the clearest window onto a mindset in which the family’s public standing and commercial position were things to be actively, strategically managed. Read against that, the philanthropy of the crisis years looks less like disinterested love of art and more like the maintenance of a reputational fortress. The word “laundering” is doing a specific job here: not money laundering in the legal sense — the money was legally earned and legally given — but the laundering of meaning, the conversion of a name associated with pills into a name associated with Rembrandt and Vermeer.

How the wall came down

The dismantling of that fortress is a study in how reputational laundering can be reversed, and it happened faster than anyone expected because it depended on a resource the Sacklers could not buy: the museums’ own reluctance to be embarrassed.

The turning point was 2019. Within a few months, a cascade of institutions announced they would no longer accept Sackler money. The National Portrait Gallery in London walked away from a promised million-pound gift; the Tate said it would take no more; the Guggenheim and the Met both announced they would refuse further Sackler donations, the Met adding that it would “review” existing naming. The pressure came from Goldin’s PAIN and allied activists staging die-ins, from a press now saturated with opioid coverage, and from the simple arithmetic that the reputational value flowed in both directions — a museum’s prestige had lent the name respectability, and now the name threatened the museum’s own standing.

The removal of the name itself came later and more grudgingly. In late 2021 the Met announced it would take the Sackler name off seven exhibition spaces, including the wing housing the Temple of Dendur, by agreement with the family. Other institutions followed at their own pace; some quietly, some with statements. Britain’s museums and universities went through their own version, with the Sackler name coming off spaces at the Serpentine, the V&A and elsewhere over the following years. A name that had taken decades to carve was, in the end, unbolted in a season.

The unbolting had a grimly literal quality that the protesters savoured. At the Serpentine, the gallery reverted to being simply the Serpentine North; at the Louvre, wall texts were quietly altered; in New York, the raised metal letters spelling the name came off the walls of the Temple of Dendur hall, leaving the faint shadow where decades of dust had settled around them. That shadow is the whole story in miniature — the name gone, the outline of it still visible, the institution having taken the money for as long as it was comfortable and removed the credit only when the discomfort exceeded the donation. The family, for its part, resisted the removals where it could and, in some settlements, negotiated the terms on which its name would come down, contesting to the end that the philanthropy had been anything other than generous.

What the reversal cannot settle

Now the fork — the part where the satisfying story and the accurate one part company.

The satisfying story says: the Sacklers bought respectability with blood money, and the world finally saw through it and tore their name down. Each clause is partly true and each is too clean.

“Bought respectability with blood money” assumes a directness the record complicates. Vast tranches of the philanthropy came from Arthur’s fortune and predate the drug entirely; to call every Sackler-named gallery a laundering of opioid profits is to convict money that was made and given before OxyContin existed. Even for the Purdue branches, the timeline is tangled — the family had been prolific donors for decades before the crisis, so the giving cannot simply be read backwards as a response to guilt it long preceded. What the documents support is narrower and more precise: that during the crisis, the protection of the name became a conscious strategic aim. That is damning enough without inflating it into the claim that every gift across three generations was a calculated purchase of cover.

And “the world saw through it” flatters the institutions. The museums did not develop a conscience; they did a risk calculation. The Sackler money had been welcome for decades while the OxyContin deaths were mounting and the company’s criminal misbranding was already a matter of public record from 2007. What changed in 2019 was the reputational cost of association. The facts about the drug were old news; what shifted was the point at which keeping the name became more embarrassing than refusing it. The institutions that took the name down had spent years lending it exactly the legitimacy the family sought. Their reversal was real and welcome; it was not a moral awakening so much as a market correction in prestige.

What the name was really for

Strip away the embellishment and a subtler, more useful truth remains, and it is not about the Sacklers alone. It is about what a name on a museum wall is for, and what it costs an institution to sell one.

Cultural institutions run on a currency of trust and prestige, and for most of a century they were willing to trade a piece of that currency for money without asking too hard where the money came from. The Sackler episode is the sharpest illustration of the bargain because the source turned out to be so specific and so lethal, but the bargain itself is old and general — the same trade the tobacco industry made with universities and research bodies, buying scientific and cultural legitimacy by the yard. The reason the die-ins landed was that they made the trade visible: bodies on the marble floor of a wing whose name existed to make you feel the opposite of that.

Nan Goldin and the activists around her understood something the museums preferred not to: that a name is a kind of argument, a claim about who deserves to be remembered and honoured, and that letting the argument stand is not neutral. When they demanded the name come down, they were doing more than punishing a family. They were refusing to let a reputational purchase go through — insisting that the culture take back the legitimacy it had sold. Whether you call the Sacklers’ giving calculated laundering or ordinary vanity that curdled into strategy under pressure, the more lasting lesson sits with the institutions that took the money: that prestige is the one asset a museum cannot afford to sell, because the buyer always intends to resell it as innocence. Understanding the transaction is worth more than deciding which Sackler to hate.